Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.53 |
| ▸ | MMP9 | P14780 | 2/20 | 0.53 |
| ▸ | ANPEP | P15144 | 2/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | LAP3 | P28838 | 1/20 | 0.53 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.53 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27770063 | 1.00 | MMP2 (0.53) | MMP2MMP9ANPEPLTA4HLAP3 | |
| SCHEMBL192802 | 0.88 | CACNA1B (0.49) | MMP2MMP9ANPEPLTA4HLAP3 | |
| SCHEMBL192801 | 0.88 | CACNA1B (0.49) | MMP2MMP9ANPEPLTA4HLAP3 | |
| SCHEMBL16789062 | 0.87 | CTSS (0.49) | MMP2MMP9ANPEPLTA4HLAP3 | |
| SCHEMBL193279 | 0.86 | CACNA1B (0.52) | MMP2MMP9ANPEPLTA4HLAP3 | |
| SCHEMBL193280 | 0.86 | CACNA1B (0.52) | MMP2MMP9ANPEPLTA4HLAP3 | |
| SCHEMBL16789066 | 0.86 | CYP2D6 (0.64) | MMP2MMP9ANPEPLTA4HLAP3 | |
| SCHEMBL16789065 | 0.84 | CTSK (0.51) | MMP2MMP9ANPEPLTA4HLAP3 | |
| SCHEMBL8512028 | 0.84 | LMNA (0.60) | CTSSCTSKCYP2D6LMNACHRM2 | |
| SCHEMBL16802186 | 0.84 | CTSK (0.48) | MMP2MMP9ANPEPLTA4HLAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6964957-B2 | Fused pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting ERAB or HADH2 activity | AGOURON PHARMACEUTICALS, INC. (US) | 2005-11-15 | — | — | US | disclosed |
| EP-1311511-A1 | PYRAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR MODULATING OR INHIBITING ERAB OR HADH2 ACTIVITY | Agouron Pharmaceuticals, Inc. (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20020132319-A1 | Peptide mutant of human ERAB or HADH2, its X-ray crystal structure, and materials and method for identification of inhibitors thereof | ABREO MELWYN A (US) | 2002-09-19 | — | — | US | disclosed |
| EP-1223176-A2 | Peptide mutant of human ERAB/HADH2, its X-ray crystal structure, and materials and method for identification of inhibitors thereof | Agouron Pharmaceuticals, Inc. (US) | 2002-07-17 | — | — | EP | disclosed |
| US-20020065292-A1 | For use in therapy of neurodegenerative diseases and certain cancers | AGOURON PHARMACEUTICALS, INC. | 2002-05-30 | — | — | US | disclosed |
| WO-2002016365-A1 | PYRAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR MODULATING OR INHIBITING ERAB OR HADH2 ACTIVITY | AGOURON PHARMACEUTICALS, INC. (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132319-A1 | Peptide mutant of human ERAB or HADH2, its X-ray crystal structure, and materials and method for identification of inhibitors thereof | ERAP1, ERAP2, ERAL1 | MMP2 851/4885MMP9 2719/4885ANPEP 50/4885 |
| US-20020065292-A1 | For use in therapy of neurodegenerative diseases and certain cancers | ERAL1, PSEN2, ERAP2 | MMP2 2553/4885MMP9 2490/4885ANPEP 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.